3 completed, 1 active not recruiting, 1 enrolling by invitation, 1 recruiting. 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Enrolling by invitation 1 |
| Phase 3 | 1 | Completed 1 |
Follow Behavioral Variant Frontotemporal Dementia (bvFTD): new trials by email Literature Review of Behavioral Variant Frontotemporal Dementia (bvFTD) trials Research Report on Behavioral Variant Frontotemporal Dementia (bvFTD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neuroinflammation in FTLD 7T MRI scan, CSF, Blood withdrawal - Corticobasal Syndrome(CBS), Primary Progressive Aphasia(PPA) | Active not recruiting | Leiden University Medical Center | 110 | 2023-07-25 | 2025-09-11 | |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP) | Recruiting | Mayo Clinic | 2100 | 2020-03-01 | 2026-10-07 | |
| Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System ECOCAPTURE, Cognitive and Behavioral experimental tasks, Neuropsychological assessment - Apathy, Behavioral Variant Frontotemporal Dementia (bvFTD) | Not applicable | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 66 | 2017-09-06 | 2026-05-20 |
| Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases 3 Tesla MRI without contrast medium, Blood sample for genetic analysis, Cerebrospinal fluid sampling (CSF) - Neurodegenerative Disease, Behavioral Variant Frontotemporal Dementia (bvFTD) | Not applicable | Enrolling by invitation | IRCCS San Raffaele | 645 | 2017-06-01 | 2026-05-05 |
| Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) FTLD, Progressive Supranuclear Palsy (PSP) | Completed | University of California, San Francisco | 1489 | 2014-09-01 | 2021-05-21 | |
| Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) TRx0237, Placebo - Behavioral Variant Frontotemporal Dementia (bvFTD) | Phase 3 | Completed | TauRx Therapeutics Ltd | 220 | 2013-05-01 | 2018-03-14 |
Supranuclear Palsy, Progressive (4) · Amyotrophic Lateral Sclerosis (3) · Corticobasal Degeneration (3) · Frontotemporal Dementia (3) · Frontotemporal Lobar Degeneration (3) · Aphasia, Primary Progressive (2) · Color Vision Defects (1) · Dementia (1) · Disease (1) · Frontotemporal Dementia With Motor Neuron Disease (1) · Lethargy (1) · Nerve Degeneration (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Neuroinflammatory Diseases (1)
Brain Diseases (6) · Central Nervous System Diseases (6) · Mental Disorders (6) · Neurocognitive Disorders (6) · Dementia (5) · Metabolic Diseases (5) · Nervous System Diseases (5) · Neurologic Manifestations (5) · Nutritional and Metabolic Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Proteostasis Deficiencies (5) · Signs and Symptoms (5) · TDP-43 Proteinopathies (5) · Basal Ganglia Diseases (4) · Cranial Nerve Diseases (4)
Blood Specimen Collection (1) · Genetic Testing (1) · hydromethylthionine (1)
IRCCS San Raffaele (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Leiden University Medical Center (1) · Mayo Clinic (1) · TauRx Therapeutics Ltd (1) · University of California, San Francisco (1)
Canada (3) · United States (3) · Italy (2) · Netherlands (2) · Australia (1) · Croatia (1) · France (1) · Germany (1) · Poland (1) · Romania (1) · Singapore (1) · Spain (1) · United Kingdom (1)
Adam Boxer, MD, PhD (1) · Adam L Boxer, MD, PhD (1) · Bradley Boeve, MD (1) · Howie Rosen, MD (1) · Prof. Massimo Filippi (1)
PMID 35790423, PMID 24819148, PMID 31551908, PMID 33827960, PMID 33851004, PMID 35492244, PMID 35653896, PMID 35700600, PMID 35751676, PMID 36155506, PMID 36658040, PMID 39345385, PMID 40754329
U19AG063911 (1), U54NS092089 (1)